Clinical Trials

Clinical trials are studies that evaluate the effectiveness of drugs or treatment routines. Our goal is to give patients the opportunity to participate in approved and exploratory therapies without long-distance travel.

Why Participate in Clinical Trials?

Clinical trials are designed to evaluate the effectiveness of new treatment interventions. The objective of clinical trials is to test new therapies in patients who have cancer. Patients participate in clinical trials for several reasons:

  • The potential to benefit from a new drug or treatment procedure
  • Improved management of symptoms resulting from the treatment of cancer
  • The opportunity to directly contribute to improving the understanding of how to treat specific cancers and ultimately, benefit other patients

Patients who participate in clinical trials receive either a promising new treatment or the best available conventional treatment. If a new treatment option is proven to work, participating patients will be among the first to benefit. While there is no guarantee that any treatment will be successful, clinical trials have been proven to offer some of the most effective cancer treatments currently available.


Our Clinical Trials

Print all clinical trials
Page:12

1479-0008

Lung Cancer

Beamion LUNG-2: A Phase III, open-label, randomized, activecontrolled, multi-centre trial evaluating orally administered BI 1810631 compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic nonsquamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations

Lines of Therapy: 1st Line Metastatic and Locally Advanced

More Details

20200041

Lung Cancer

A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

Lines of Therapy: Other

More Details

20210031

Melanoma

A Randomized, Double-blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared with Opdivo (Nivolumab) in Subjects with Treatment-naïve Unrespectable or Metastatic Melanoma

Lines of Therapy: 1st Line Metastatic and Locally Advanced

More Details

61186372NS2012 COPERNICUS

Lung Cancer

A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Lines of Therapy: 1st Line Metastatic and Locally Advanced, 2nd Line Metastatic

More Details

61186372NSC2007

Lung Cancer

A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib

Lines of Therapy: 1st Line Metastatic and Locally Advanced

More Details

BGB-3111-308

Lymphoma

A Phase 3, Open-Label Study of Zanubrutinib Plus Anti-CD20 Versus Rituximab and Lenalidomide (R2) in Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Lines of Therapy: Other

More Details

J3M-MC-JZQB SUNRAY-01

Lung Cancer

A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression

Lines of Therapy: 1st Line Metastatic and Locally Advanced

More Details

PUMA-ALI-1201

Breast Cancer

A PHASE 2 STUDY OF ALISERTIB IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH HR+, HER2-NEGATIVE RECURRENT OR METASTATIC BREAST CANCER

Lines of Therapy: 3rd Line + Metastatic

More Details

TP-CA-002

Lung Cancer

TEMPUS GEMINI NSCLC SURVEILLANCE STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Non-Small Cell Lung Cancer (NSCLC)

Lines of Therapy: Neo-Adjuvant, 1st Line Metastatic and Locally Advanced

More Details

Page:12